Compounding pharmacies can resume making tirzepatide
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
Hims & Hers Stock Soars 7% as FDA Reconsiders Limits on Compounded Weight-Loss Drugs
Hims & Hers Health saw its shares surge by 7% today after the FDA announced that it would reconsider its decision to limit compounded weight-loss drugs, following a lawsuit from t
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage.
Hims & Hers surges as FDA mulls over compounded drugs limit
The Food and Drug Administration (FDA) is reconsidering its limit on compounded weight-loss drugs, or custom-made medications that combine or mix certain ingredients. In response, Hims & Hers Health (HIMS) shares have jumped on this news.
FDA Reversal on Knockoff GLP-1 Drugs Brings Confusion, and Few Answers
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
pharmaphorum22h
FDA rethinking block on compounding of Lilly's obesity drug
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...